Inventiva S.A. SEC filings IVEVF
Inventiva S.A. has 228 filings in SEC EDGAR's recent list, going back to Apr 10, 2020. Its latest annual report, Form 20-F, was filed on Apr 8, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 6, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 27, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 1, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 30, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Nov 19, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Nov 19, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 13, 2025 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Oct 21, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jul 31, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jun 20, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | May 9, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | May 7, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 14, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Mar 31, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Mar 26, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Dec 23, 2024 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 13, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Oct 21, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Oct 21, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jul 19, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | May 3, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 9, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Sep 25, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Sep 5, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 11, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Feb 10, 2021 | — |
| SC 13G | Ownership over 5% (passive) | Feb 10, 2021 | — |
| SC 13G | Ownership over 5% (passive) | Feb 9, 2021 | — |
| SC 13D | Ownership over 5% (active) | Jul 21, 2020 | — |
| SC 13D | Ownership over 5% (active) | Jul 20, 2020 | — |
Showing 43 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IVA (Nasdaq), IVEVF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- France
- Headquarters
- Daix, France
- SEC filer status
- Accelerated filer
- SEC CIK
- 1756594
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.